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Abstract 
Bone marrow monocytes are primarily committed to osteoclast formation. It is, however, 
unknown whether potential primary alterations are specifically present in bone marrow 
monocytes of multiple myeloma patients, smoldering myeloma or monoclonal gammopathy 
of uncertain significance. Herein, we analyzed the immunophenotypic and transcriptional 
profiles of bone marrow CD14+ monocytes in a cohort of patients with different types of 
monoclonal gammopathies to identify alterations involved in myeloma-enhanced 
osteoclastogenesis. A higher number of bone marrow CD14+CD16+ cells was found in 
patients with active myeloma as compared to those with smoldering myeloma and 
monoclonal gammopathy of uncertain significance. Interestingly, sorted bone marrow 
CD14+CD16+ cells from myeloma patients were more pro-osteoclastogenic than 
CD14+CD16- cells in cultures ex vivo. Moreover, transcriptional analysis demonstrated that 
bone marrow multiple myeloma (but neither monoclonal gammopathy of uncertain 
significance nor smoldering myeloma) CD14+ cells significantly upregulated genes involved 
in osteoclast formation, including IL21R. IL21R mRNA over-expression by bone marrow 
CD14+ cells was independent from the presence of IL-21. Consistently, IL-21 production by 
T cells as well as IL-21 bone marrow levels were not significantly different among 
monoclonal gammopathies. Thereafter, we showed that IL21R over-expression in CD14+ 
cells increased osteoclast formation. Consistently, IL-21R signaling inhibition by Janex 1 
suppressed osteoclast differentiation from bone marrow CD14+ cells of myeloma patients. 
Our results indicated that multiple myeloma patients showed distinct bone marrow monocyte 
features compared to those with indolent monoclonal gammopathies, supporting the role of 
IL21R over-expression by bone marrow CD14+ cells in enhanced osteoclast formation. 
Keywords: Multiple myeloma, Monoclonal gammopathy of undetermined significance, 
Bone marrow microenvironment, Osteoclast, Monocyte 
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INTRODUCTION 
Multiple myeloma (MM) is characterized by bone destruction, osteolytic lesions and 
consequently a higher fracture risk1 due to an increase in bone marrow (BM) osteoclast (OC) 
formation and osteoblast suppression.2-4 Conversely, patients with indolent gammopathies 
such as smoldering MM (SMM) and monoclonal gammopathy of uncertain significance 
(MGUS) are characterized by the absence of lytic lesions, although an increase in OC bone 
resorption may occur.5-9 
Since the close relationship between plasma cells (PCs) and BM microenvironment plays a 
pivotal role in MM pathogenesis,10 ongoing studies are focusing on the presence of potential 
molecular alterations in the microenvironment.11-13 Transcriptional profile alterations have 
been reported in mesenchymal stromal cells (MSCs) and osteoblasts of MM patients 
correlated to osteolytic lesions and when compared to healthy donors but not MGUS 
patients.13 BM monocytes play a pivotal role in bone disease,2, 4, 14 angiogenesis15 and 
immune system dysfunction,16 which are hallmarks of active MM. 
Enhanced bone resorption in MM patients occurs in the BM in close contact with PC 
infiltration.5 Contact between MM cells and BM stromal cells stimulates the production of 
the Receptor Activator of Nuclear factor Kappa-B Ligand (RANKL), the main pro-
osteoclastogenic cytokine involved in OC differentiation, through its receptor RANK on 
monocytes surface.2, 17 Moreover, different factors produced by MM cells can stimulate 
osteoclastogenesis including Interleukin (IL)-618 and the Macrophage Inflammatory Protein 
(MIP)-1α.19, 20 Recently, it has also been reported that IL-3 is increased in BM plasma from 
MM patients and that it induces Activin A production by BM monocytes which in turn 
stimulates osteoclastogenesis in a RANKL-independent mechanism.21 This suggests that BM 
monocytes may be directly involved in enhanced osteoclastogenesis in MM.  
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Immunophenotypic analysis of peripheral monocytes demonstrates that CD14+CD16+ sub-
population accounts for 5–10% of monocytes in healthy individuals but resulted significantly 
expanded in cancer22 and inflammatory conditions.23, 24 In psoriatic arthritis, CD14+CD16+ 
cells have been associated to bone erosion and identified as the main source of OC 
progenitors.25 More recently, it has been reported that the proportion of CD14+CD16+ cells 
increased in MM patients with the tumor load26, 27 and these cells are potential markers of OC 
progenitors.27 However, the presence of alterations in the BM monocytes in MM patients is 
still unknown. Thus, the aim of this study was the characterization of the immunophenotypic 
and transcriptional profiles of the BM CD14+ cells across a cohort of patients with different 
types of monoclonal gammopathies in order to identify genes that are potentially involved in 
enhanced osteoclastogenesis and possibly druggable as new therapeutic targets. 
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METHODS 
Patients 
A total cohort of 50 patients with newly diagnosed active MM 32 patients with smoldering 
MM (SMM), and 20 patients with monoclonal gammopathy of undetermined significance 
(MGUS) admitted to our hematological Institution from 2010 until 2016 were included in the 
analysis of monocytes features. All of the subjects involved in the study gave their written 
informed consent, according to the Declaration of Helsinki. The University of Parma’s 
Institutional Review Board (Parma, Italy) approved all the study protocols. To define the 
presence of osteolytic lesions in MM patients we used the X-ray skeletal survey as first 
imaging procedure and alternatively a CT low dose scan or CT/PET scan evaluations, as 
recently updated by the International Myeloma Working Group.28 The evaluation of the 
skeleton was performed in MM patients at the same period of the BM aspirates. The presence 
of at least one lytic lesion on X-ray or CT/PET scan was used to define osteolytic patients. 
The presence of equal or more than three lytic lesions was used to define high bone disease 
(HBD) patients. MM patients with low bone disease (LBD) were considered with minus of 3 
lytic lesions or without bone lesions.29 
Specifically, patient samples were not suitable for all the analysis performed. Table 1 reports 
the number of patients analyzed  by the different techniques used in the study. 
Primary cell isolation and characterization. 
Immunophenotype. Details of the immunophenotype analysis performed were reported in on-
line Supplemental data.  
Isolation of primary CD14+ cells and CD14+ cell sorting from BM samples. 
CD14+ monocytes were isolated from BM and peripheral blood (PB) mononuclear cells 
(MNCs) by immunomagnetic method with anti-CD14 mAb conjugated with microbeads 
(Miltenyi Biotech; Bergisch-Gladbach, Germany). 
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With the same protocol, CD138+, CD3+, CD4+ and CD8+ cells were isolated from BM 
samples. The presence of potential contaminating cells in each fraction was evaluated by flow 
cytometry analysis, using the fluorescence-activated flow cytometer BD FACS Canto II with 
Diva software (Becton, Dickinson and Company (BD); Franklin Lakes, NJ). Purity of 
monocyte samples was >92% and an example of purity analysis is shown in Supplemental 
Figure 1. All the Abs (anti-human CD14-PerCP-Cy5.5, clone MφP9; anti-human CD138 PE, 
clone MI15; anti-human CD3 FITC, clone SK7; anti-human CD4 FITC, Clone L120; anti-
human CD8 PE, Clone SK1) were obtained from BD. 
Primary BM MSCs were obtained from the CD14-CD138- fraction of BM MNCs. Cells were 
incubated until confluence for 2 weeks in alpha minimum essential medium (αMEM) 
supplemented with glutamine, at 15% fetal bovine serum (FBS) (all these reagents purchased 
from Invitrogen Life Technologies; Carlsbad, CA). 
For CD14+ cell sorting, purified BM CD14+ cells were stained with PE-Cy7-conjugated anti-
CD16 Ab and sorted according to the gating strategy shown in Supplemental Figure 2. The 
cells and gates were analyzed by FACSDivaTM 7 software (BD) and the cell sorting 
performed on the FACS Aria III instrument. 
Fluorescence in situ hybridization (FISH), microarrays analysis and Real Time PCR. 
These methodologies were detailed in Supplemental Methods section of on-line 
Supplemental data. 
Cell culture conditions. 
Monocyte treatment with cytokines. 
Primary CD14+ cells were cultured in the presence or absence of recombinant human (rh) IL-
21 (30 pg/ml) (Biovision Inc.; Milpitas, CA) for 24 h and then collected for mRNA analysis. 
The human monocytic cell line THP-1 was purchased from the American Type Culture 
Collection (Rockville, MD), recently authenticated and tested for mycoplasma contamination. 
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THP-1 cells were treated with rhIL-6 (20 ng/ml) (Thermo Scientific; Rockford, IL) and/or rh 
Tumor necrosis factor (TNF)-α (10 ng/ml) (OriGene; Rockville, MD) for 48 h and then 
collected for mRNA analysis. 
Lentiviral infections. 
The amplified IL21R complementary DNA sequence was cloned into the pLenti-GIII-CMV-
GFP-2A-Puro lentiviral vector (Applied Biological Materials Inc.; Richmond, Canada). 
Recombinant lentivirus was produced by transient transfection of 293T cells.30 Primary 
CD14+ cells were transduced following published protocols.31 Briefly, 8x106 CD14+ cells 
purified from PB buffy coats of healthy donors were placed in well plate in 2 ml of αMEM 
with 10% FBS and rhM-CSF (25ng/ml) (Peprotech; Rocky Hill, NJ) in the presence of either 
empty or IL21R vector. As a control, CD14+ cells were also seeded in the same conditions 
without adding the lentiviral vector. After 18 h, 2 ml of fresh αMEM with 10% FBS and 
rhM-CSF (25 ng/ml) were added. After 3 days, cells were collected and seeded for 
osteoclastogenesis assays and for IL21R mRNA analysis. 
Osteoclastogenesis assays. 
After cell sorting, both CD14+CD16- and CD14+CD16+ populations were seeded 2x105 
cells/well in 96well plates in αMEM with 10% FBS, rhM-CSF at 25 ng/ml and rhRANKL 
(Peprotech) at 60 ng/ml and then cultured for 28 days, replacing half medium every 2-3 days. 
In another osteoclastogenesis assay setting, 2x105 lentiviral transduced CD14+ cells/well 
were seeded in 96well plates in αMEM medium with 10% FBS, rhM-CSF 10ng/ml and 
rhRANKL 50 ng/ml and the IL-21R signaling inhibitor Janex 1 (10 µM) (Cayman Chemical 
Company; Ann Arbor, MI) and then cultured for 28 days, replacing half medium every 2-3 
days. 
Finally, in the third osteoclastogenesis assay setting, MM BM MNCs or purified BM CD14+ 
cells were used (n=18). 4x105 MNCs or 2x105 CD14+ cells/well were seeded in 96well plates 
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in αMEM with 10% FBS, rhM-CSF 25 ng/ml and rhRANKL 20 or 60 ng/ml in presence or 
absence of rhIL-21 (30 pg/ml) and Janex 1 (10 µM), and then cultured for 28 days, replacing 
half medium every 2-3 days. 
In all in vitro osteoclastogenesis assays, each condition was performed at least in triplicate. 
The OCs were identified and counted by light microscopy at the end of the culture period as 
multinucleated (>3 nuclei) cells positive for tartrate resistant acid phosphatase (TRAP) assay 
(Sigma Aldrich; Saint Louis, MO). OC areas were quantified using ImageJ software (U.S. 
National Institutes of Health, Bethesda, MD). 
STAT3 activity assay. 
The specific procedures were detailed in Supplemental Method section of on-line 
Supplemental data. 
BM IL-21 levels in patients with monoclonal gammopathies. 
The levels of IL-21 in BM plasma were measured by ELISA method as reported in on-line 
Supplemental data.  
Statistical analysis. 
Quantitative variables were compared by not-parametric Kruskal-Wallis and Mann-Whitney 
test, or parametric two-tail Student’s t test. Results were considered significant at p<0.05. 
GraphPad Prism 5.0™ was used for all the statistical analyses. 
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RESULTS 
MM patients show a higher number of BM CD14+CD16+ cells compared to MGUS. 
The immunophenotype of BM CD14+ cells was evaluated in BM aspirates of 28 active MM 
patients (median age 73 years, range 48-89; 46% female (F), 54% male (M); International 
Staging System (ISS): I=3 , II=8, III=17 ); 15 SMM (median age 57 years, range 38-82; 33% 
F, 67% M) and 9  MGUS (median age 57 years, range 37-78; 44% F, 54% M). 48% of active 
MM patients had evidence of osteolytic lesions. A representative example of flow cytometry 
analysis is reported in Figure 1A. 
We found that the median % of CD14+CD16+ cells in BM samples significantly increased 
across the different types of monoclonal gammopathies from MGUS to active MM: MGUS: 
1.9% (range: 0-3%), n=9; SMM: 3.5% (range: 1.0-7.5%), n=15; active MM: 5.25% (range: 0-
20.0%), n=28; p=0.0071.  
In particular a statistically significant difference was observed comparing MM and MGUS 
patients (p=0.0144) (Figure 1B).  
There was no statistical difference in the median % of BM CD14+CD16+ population between 
osteolytic MM patients (n=13) versus not-osteolytic ones (n=15): 4% (range 0-20%) versus 
7.8% (range 0-20%), respectively (Figure 1C). Similarly, comparing MM patients with HBD 
(n=9) versus those with LBD (n=19), we did not find a statistically significant difference in 
the median % of BM CD14+CD16+ population: 4.7% (range 0-20%) versus 5.5% (range 0-
20%), respectively (Figure 1D).  
In the same way, analyzing all myeloma patients (SMM and MM), there was no significance 
difference between the osteolytic patients compared to those without osteolytic lesions 
[osteolytic MM (n=13) versus not-osteolytic MM plus SMM (n=30): 4% (range: 0-20%) 
versus 4.3% (range: 0-20%)]. 
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BM CD14+CD16+cells in MM patients are pro-osteoclastogenic in ex vivo cultures. 
To investigate whether the increased number of CD14+CD16+ cells observed in the BM 
samples of MM patients could be associated with an enhanced pro-osteoclastogenic activity, 
we sorted the BM CD14+CD16+ monocyte population by FACS and then tested its ex vivo 
pro-osteoclastogenic differentiation properties in comparison with the CD14+CD16- cell 
fraction. A representative example of flow cytometry analysis of monocyte sub-populations 
before and after cell sorting was reported in Supplemental Figure 2. A median value of 
3.5x105 of CD14+CD16+ was obtained after cell sorting from MM BM samples. Due to the 
limited numbers of cells, we were only able to perform osteoclastogenesis assays. 
Interestingly, we found that CD14+CD16+ cells generated more TRAP positive cells with a 
higher number of OCs showing 5 or more nuclei than CD14+CD16- population (Figure 1 E). 
 
A different transcriptional fingerprint characterizes BM CD14+ cells in MM patients as 
compared to SMM and MGUS. 
We performed gene expression profiles of purified primary BM monocytes. We checked the 
intensity value of specific CD14 and CD138 probe sets (Supplemental Table 1) and discarded 
9 samples displaying high CD138 expression from the analysis to further ensure to exclude 
the presence of malignant PCs in the analysis. Hence, BM monocyte samples included in the 
gene expression analysis were obtained from 23 MM, 15 SMM and 9 MGUS patients. The 
main characteristics of patients eligible for gene expression analysis were reported in Table 2. 
Unsupervised analysis significantly clustered together MM samples (p=0.0024, Fischer’s 
exact test) whereas SMM and MGUS were scattered along the dendrogram. (Figure 2A). A 
multiclass analysis identified 99 differentially expressed genes in CD14+ cells between the 
three classes of patients (Supplemental Figure 3A; Supplemental Table 2), whereas 78 genes 
(18 up- and 60 down-regulated) were differentially expressed in monocytes of MM patients 
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as compared to SMM (Supplemental Figure 3B; Supplemental Table 3). The comparison of 
MM with asymptomatic samples (SMM and MGUS) identified 254 genes differentially 
expressed in CD14+ cells, specifically, 62 up-regulated and 192 down-regulated genes 
(Supplemental Figure 3C; Supplemental Table 4). Functional annotation analysis of genes 
differentially expressed in symptomatic patients was performed using standard procedure in 
Database for Annotation, Visualization and Integrated Discovery (DAVID) and Gene Set 
Enrichment Analysis (GSEA) tools (Table 3). Among the identified gene sets, it is worth 
mentioning those associated with the Cytokine-cytokine receptor interaction pathway, Jak-
STAT signaling pathway, and the interferon alpha and gamma responses. Among the 
differentially expressed genes, chemokines and chemokine and cytokine receptors with pro-
osteoclastogenic properties such as CCR5, IL21R and CD40, were specifically up-regulated 
in CD14+ of MM patients. Importantly, monocytes in MM samples up-regulate SLAMF7, 
which is selectively expressed in plasma cells and natural killer cells in MM leading to 
antibody-dependent cellular cytotoxicity and direct natural killer cell activation.32 
Particularly, IL21R over-expression by BM CD14+ in MM patients was demonstrated (q-
value=0), either in the multiclass analysis or comparing MM versus SMM plus MGUS 
(Supplemental Table 2 and 4). Interestingly, IL21R gene expression in the complete database 
significantly correlated with the expression of CCR5 (p=0.0197), CD40 (p<0.0001), and 
SLAMF7 (p=0.0002) genes (Figure 2B). Moreover a further analysis between osteolytic 
versus not-osteolytic active MM patients identified 12 genes (SERPINB10; CDCA5; MYBL2; 
SELENBP1; TK1; GYPA; KIF18A; SPC25; HJURP; TAL1; SKA1) down regulated in not-
osteolytic MM patients. On the other hand, we did not find a significant different gene 
expression signature between  high bone disease versus low bone disease active MM patients. 
Thereafter, in a subgroup of patients, we confirmed a significant up-regulation of IL21R, 
CCR5, CD40, and SLAMF7 genes in CD14+ cells from MM patients compared to SMM 
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and/or MGUS, by Real Time PCR (Figure 2C). Consistently with the GEP data, we did not 
find a significant different expression of IL21R, CCR5, CD40, and SLAMF7 genes between 
osteolytic versus not-osteolytic active MM patients (Figure 2D).  
BM CD14+ cells over-express IL21R mRNA in MM patients irrespective of IL-21. 
Based on the gene expression data and the previous evidences that IL-21 is a growth factor 
for MM cells33, 34 and IL-21/IL21R axis promotes osteoclastogenesis and bone destruction in 
pathological conditions35, 36 we further investigated the possible role of IL21R over-
expression by CD14+ cells in MM-induced osteoclastogenesis. 
Firstly, by means of Real Time PCR, we confirmed that IL21R mRNA levels significantly 
increased in BM CD14+ cells across different PC dyscrasias in a cohort of patients with MM, 
SMM and MGUS (p=0.036) (Figure 3A). We showed that BM CD14+ cells expressed 
significantly higher levels of IL21R mRNA in MM patients as compared to MGUS (p=0.023, 
Figure 3A), and in MM compared to SMM plus MGUS patients (p=0.005, Figure 3B). The 
up-regulation of IL21R mRNA was also observed in MM CD14+ cells obtained from PB 
(n=3, data not shown). The mean difference between IL21R expression (expressed as -ΔCt) 
by BM and PB monocytes purified from the same patient was 0.46±0.49 (p= 0.64). The 
expression of IL-21R was also investigated at protein level by flow cytometry: in line with 
the evidence that CD14+CD16+ population was increased in MM patients, we found that BM 
CD14+ cells in MM patients expressed IL-21R/CD360 and that CD14+CD16+ population 
showed higher median fluorescence intensity (MFI) compared to CD14+CD16- cells in each 
tested patient (mean ΔMFICD14+CD16+-MFICD14+CD16- ±SD= 6.1±2.4) (Figure 3C). 
Furthermore, we checked the levels of active STAT3 in BM CD14+ cells, as it is well known 
that the signaling pathway down-stream of IL-21R leads to the activation of Jak3 and 
STAT3.37, 38 We found that MM CD14+ cells had significantly higher levels of active STAT3 
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compared to MGUS (p=0.0029) and asymptomatic ones (MGUS plus SMM) (p=0.0093, 
Figure 3D). 
To investigate the possible mechanisms involved in IL21R mRNA over-expression, we 
treated purified BM CD14+ cells obtained from MM or SMM or MGUS patients with the 
rhIL-21 concentration reached in the BM plasma of our cohort of patients. The addition of 
rhIL-21 (30 pg/ml) slightly increase IL21R mRNA in BM CD14+ cells from MGUS and 
SMM patients but not from MM patients, without reaching the statistically significance 
difference (Figure 3E), suggesting a constitutive IL21R mRNA expression in MM patients 
irrespective of the presence of IL-21. On the other hand, using the well-establish39 monocytic 
cell line THP-1, we found that the combined treatment with pro-inflammatory cytokines 
rhIL-6 (20 ng/ml) and rhTNF-α (10 ng/ml) significantly increased IL21R mRNA expression 
compared to untreated controls (p=0.005, Figure 3F). 
BM IL21 expression and levels did not significantly differ across patients with 
monoclonal gammopathies. 
Next, we evaluated IL21 mRNA expression levels in our cohort of patients. BM MSCs, 
CD14+ and primary MM cells did not express IL21 gene, which was otherwise expressed by 
CD3+ cells, in the CD4+ fraction, checked by Real Time PCR (Supplementary Table 5 ). We 
failed to find a significant difference in IL21 mRNA expression by CD3+ cells among MM, 
SMM and MGUS patients, as reported in Figure 4A. Consistently, no significant difference 
was found in BM levels of IL-21 across the different monoclonal gammopathies, as detected 
by ELISA (Figure 4B). The median BM IL-21 level was of 32.4 pg/ml for MGUS, 24.4 
pg/ml for SMM and 34.1 pg/ml for newly diagnosed MM patients. 
IL21R over-expression by CD14+ cells is involved in osteoclastogenesis. 
Since IL21R has been identified among the genes over-expressed by BM CD14+ cells in MM 
patients, we therefore investigated its role in OC differentiation. We induced IL21R over-
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expression in CD14+ cells obtained from 3 different healthy donors. The over-expression of 
IL21R gene was evaluated by Real Time PCR in CD14+ cell infected with IL-21R vector 
(CD14+ IL21R vector) and compared to those infected with the empty vector (CD14+ empty 
vector, Figure 5A). Subsequently, we performed in vitro osteoclastogenesis assays. The 
number of OCs in this set of experiments was low because the infection with lentiviral 
vectors highly affects primary monocyte viability (Figure 5B-C). Interestingly, in vitro 
osteoclastogenesis assays showed that the over-expression of IL21R increased the number 
and median area of OCs in the presence of RANKL and M-CSF compared to controls; 
consistently, the presence of Janex 1, a JAK3 inhibitor known to block IL-21R signaling, 
significantly reduced OC formation and size in CD14+ IL21R vector cells (Figure 5B-C). 
Blocking IL-21R signaling inhibits osteoclastogenesis. 
To further confirm the role of IL21R over-expression in osteoclastogenesis, we performed in 
vitro osteoclastogenesis assays with or without rhIL-21 in the presence or absence of Janex 1. 
The presence of rhIL-21 did not affect the number and the area of TRAP positive OCs 
obtained from total MNCs or CD14+ cells purified from MM BM aspirates (Figure 6A-B). 
Any significant difference was not found in the number and in the OC area between tumor 
and not-tumor samples treated with IL-21 (data not shown). 
On the other hand, Janex 1 significantly suppressed osteoclastogenesis, either from total BM 
MNCs or from BM CD14+ cells obtained from MM patients, both in the presence (p<0.001) 
and in absence (p<0.001) of the rhIL-21, as shown in Figure 6 A-B. Moreover, the presence 
of Janex 1 significantly reduced the median OC area both in the presence (p=0.012) and in 
absence (p<0.001) of the rhIL-21 compared to untreated controls (Figure 6A). 
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DISCUSSION 
Monoclonal gammopathies are characterized by the activation of bone resorption with 
progressive increase in the number of OCs from MGUS to MM.5 Several studies have 
evaluated the gene expression profiles of PCs obtained both from patients with newly 
diagnosed MM and MGUS and from healthy donors to identify genes potentially related to 
the progression of MM.40, 41 However, while MGUS and MM can be distinguished from 
normal PCs, these two conditions cannot be easily differentiated from each other.40, 41 The 
transcriptional data were used to stratify MM patients with lytic lesions, identifying DKK1 as 
the main over-expressed gene when focal bone lesions occur.42 Studies analyzing the BM 
microenvironment cells indicate that MSCs and osteoblasts in MM patients have different 
transcriptional profiles, in comparison with healthy donors and based on the occurrence of 
osteolytic lesions.13 However, all the BM biological alterations from MGUS to SMM and, 
finally, to active MM are not yet clear.  
As regards the immunophenotypic profile, we found that the median percentage of 
CD14+CD16+ cells in BM samples increased among the different types of monoclonal 
gammopathies, resulting significantly higher in MM versus MGUS. In our study, for the first 
time we sorted BM CD14+CD16+ cells and showed that they represent the osteoclastogenic 
fraction of CD14+ cells in MM patients, supporting the notion that inflammatory monocytes 
are involved in MM-induced osteoclastogenesis. In addition, CD14+CD16+ cells might 
contribute to the high production of inflammatory cytokines, such as TNF-α,23 that are 
increased in the BM of MM patients and involved in OC formation.43, 44  
Consistent with the immunophenotypic profile, the transcriptome of CD14+ obtained from 
MM patients showed the up-regulation, as compared to SMM and MGUS, of genes involved 
in immune response, chemotaxis and osteoclastogenesis. We focused on genes potentially 
involved in osteoclastogenesis. Among the up-regulated genes, we found CCR5, whose role 
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in bone destruction in MM has already been extensively investigated.19, 20 IL21R mRNA was 
also over-expressed by BM CD14+ cells in MM but not in SMM or MGUS.  
The analysis between osteolytic versus not-osteolytic active MM patients identified only few 
12 genes down regulated in not-osteolytic MM patients. Nevertheless, we did not find a 
significant different gene expression signature between high bone disease versus low bone 
disease active MM patients. The lack of major differences in the immunophenotypic and 
transcriptional profiles of monocytes between osteolytic and not osteolytic are not surprising 
because the main pathophysiological difference between osteolytic and non osteolytic MM 
patients is the suppression of osteoblast formation rather than the increases osteoclast 
formation and activity. Our data are supported by previous studies reporting that all MM 
patients have a significant increase of bone resorption rate with an unbalanced bone 
remodeling.5, 9 In addition,  MGUS  patients have a significant increase of bone resorption 
rate.5, 7 Consistently in this study we lack to find a large number of differentially expressed 
genes by monocytes across patients with the different monoclonal gammopathies.  
In this study, we demonstrated the potential involvement of IL-21/IL-21R axis in increased 
osteoclastogenesis that occurs in MM patients. The ligand of IL-21R, the cytokine IL-21, is a 
growth factor for MM cells33, 34 and it is mainly produced by T cells.37, 45 The binding of IL-
21 to its receptor leads to the activation of the Jak–STAT pathway, in particular Jak1, Jak3, 
STAT1, and STAT3.37, 46, 47 Interestingly, a previous study showed that IL-21 up-regulation 
in the synovium and the serum of rheumatoid arthritis patients is involved in 
osteoclastogenesis and bone destruction.35 Nevertheless, its role in MM-induced OC 
formation is largely unknown. In this study we found a significant IL21R mRNA over-
expression by CD14+ cells correlated with the other osteoclastogenic genes identified such as 
CCR5, but also with CD40 and SLAMF7. Interestingly, in line with the immunophenotypic 
profile of BM CD14+ in MM patients, IL21R was expressed at high intensity in the 
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CD14+CD16+ fraction. The up-regulation of IL21R in MM patients was associated with an 
increase of STAT3 signaling and independent from the presence of IL-21. On the other hand, 
as the combination of the pro-inflammatory cytokines IL-6 and TNF-α increase IL21R 
mRNA expression in monocytes, we might suppose that these cytokines are involved in 
IL21R over-expression by BM CD14+ cells. The pathophysiological role of IL21R over-
expression by CD14+ cells in enhanced osteoclastogenesis occurring in MM patients was 
further demonstrated by a lentiviral approach. These data also supported the role of IL-21R 
signaling as a potential therapeutic target. Accordingly, it is worth remembering that the 
clinically approved JAK3 inhibitor Tofacitinib suppresses OC-mediated structural damage to 
arthritic joints and decreases RANKL production.48 This study is not designed to evaluate the 
role of IL-21R overexpression as a potential biomarker of MM progression, however our data 
suggest that IL-21R expression level could be a potential biomarker of myeloma progression. 
Clearly, only an appropriate prospective study evaluating the IL-21R expression could 
address to this point.  
In conclusion, the study supports the notion that a pro-inflammatory profile of BM CD14+ 
cells is involved in osteoclastogenesis in MM patients, in line with a considerable amount of 
evidences from literature.19, 49, 50 For the first time, we highlighted IL21R over-expression in 
BM monocytes from MM patients and demonstrated its role in increased osteoclastogenesis, 
suggesting that IL-21R signaling could be a potential new therapeutic target for MM bone 
disease. 
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TABLES 
Table 1: Number of patients analyzed for the monocytes features by the different 
techniques.  
 
 Immunophenotype GEP Real Time PCR 
MGUS 9 9 6 
SMM 15 15 11 
MM 28 32* 13 
    Abbreviations: GEP= gene expression profile 
*= 9 out of 32 samples, displaying high CD138 expression, were excluded from the statistical 
analysis. 
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Table 2: Main clinical characteristics of the cohort of patients eligible for gene 
expression analysis.  
 
       MM cell genetic alterations 
Patient sex age ISS osteolysis HBD type del(13q) H del(17p) t(11;14) t(4;14) t(14;16) 
MGUS1 F 43 
   
l 
      MGUS2 F 52 
   
l 
      MGUS3 M 42 
          MGUS4 M 78 
   
k 
      MGUS5 F 54 
   
l 
      MGUS6 M 77 
   
k - 
 
- - - - 
MGUS7 M 43 
   
k 
      MGUS8 M 91 
   
l 
      MGUS9 F 50 
          
SMM1 F 67 
 
 
 
l 
      SMM2 F 72 
 
 
 
l - + - - + - 
SMM3 F 58 
 
 
 
l 
      SMM4 M 58 
 
 
 
k 
      SMM5 F 64 
 
 
 
k 
      SMM6 F 61 
 
 
 
l 
      SMM7 F 64      k - + - - - - 
SMM8 M 56 
 
 
 
k 
      SMM9 M 70 
 
 
 
k - - - 
   SMM10 F 67 
 
 
  
- 
 
- 
   SMM11 F 76 
 
 
 
k 
      SMM12 M 83 
 
 
 
k + - - + - - 
SMM13 M 47 
 
 
 
k 
      
SMM14 M 41 
 
 
 
k 
      
SMM15 M 65 
 
 
 
k + - - - + - 
MM1 M 83 III + - l 
      MM2 M 75 III 
  
k 
      MM3 F 59 II + - k + 
 
- - - + 
MM4 F 80 II - - l + 
 
+ - - - 
MM5 M 76 II - - l + 
 
- + - - 
MM6 F 79 II - - l + - - - - 
 MM7 M 69 I + + k 
      MM8 M 79 II + + l 
      MM9 M 57 I + - l + -  + 
   MM10 M 81 II + + k - + - - - - 
MM11 M 60 II 
  
k 
      MM12 F 78 II 
  
l - 
 
- - - - 
MM13 M 73 III + + k 
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Abbreviations: MGUS, Monoclonal Gammopathy of Undetermined Significance; SMM, 
Smoldering Multiple Myeloma; MM, Multiple Myeloma; F, female; M, male; ISS, 
International Staging System; HBD, High Bone Disease; H, Hyperdiploid. 
MM14 M 74 II + + l - 
     MM15 F 73 II - - l - 
 
- + - - 
MM16 M 70 I - - k - - - 
   MM17 F 84 III - - k + - - - - - 
MM18 F 86 III 
  
l 
      
MM19 M 73 II + - l - - - - - - 
MM20 M 56 III - - k 
      
MM21 F 50 II + + k + - - + - - 
MM22 F 75 I + + k 
  
- 
   
MM23 F 77 III - - k - - 
 
- - - 
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Table 3:  Functional annotations* of the representative genes distinguishing BM monocytes 
arisen from supervised analysis of MM versus (MGUS plus SMM) patients. 
Database for Annotation, Visualization and Integrated Discovery (DAVID )  
Pathway Database Term Genes§ 
KEGG 
Cytokine-cytokine receptor interaction CCR5, IL21R, CSF3R, CD40 
Jak-STAT signaling pathway IL21R, CSF3R,  
Chemokine signaling pathway GNGT2, CCR5 
REACTOME  Metabolism of carbohydrates GOT2, GPI, PGM1, PGD, GYS1,  
   
Gene Set Enrichment Analysis (GSEA)  
Functional group category  Genes§ 
INTERFERON ALPHA RESPONSE EPSTI1, IFI27, IFITM1, ISG20, LAP3     
INTERFERON GAMMA RESPONSE 
CD40, EPSTI1, IFI27, ISG20, LAP3, PIM1, SLAMF7, STAT4, 
VAMP5      
 
*DAVID Functional Annotation Tool v6.8 (https://david.ncifcrf.gov) and GSEA tool 
(http://software.broadinstitute.org/gsea) were used to classify genes into functional 
categories. 
§ Genes down-regulated in MM monocytes are underlined. 
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FIGURE LEGENDS 
Figure 1: Immunophenotype of BM monocytes in patients with monoclonal 
gammopathies and their pro-osteoclastogenic ex vivo properties. 
(A) CD14 and CD16 expression by BM monocytes in patients with monoclonal 
gammopathies: example of plots of flow cytometry data. (B) Box plot represents the median 
percentage values of CD14+CD16+ cells evaluated in BM samples obtained from patients 
with MGUS, SMM and MM (p calculated by Mann-Whitney test).  Box plot represents the 
median percentage values of CD14+CD16+ cells evaluated in BM samples obtained from 
patients with (w)  or without (w/o) osteolysis (C) and from patients with high bone disease 
(HBD) or low bone disease (LBD) (D). 
CD14+ cells were purified from BM samples of patients with monoclonal gammopathies by 
an immunomagnetic method and then sorted in the two sub-populations CD14+CD16- and 
CD14+CD16+ by a Flow cell sorter as described in Materials and methods section. 
CD14+CD16- or CD14+CD16+ cells (200.000 cells/well) were seeded in 96well plates in 
αMEM medium at 10% FBS with rhM-CSF 25ng/ml and rhRANKL 60ng/ml. After 28 days 
of culture, OCs were identified as multinucleated TRAP positive cells and counted by light 
microscopy. (E) Bar graph represents the median number of OCs/well of each condition, 
divided into OCs with ≥5 nuclei or <5 nuclei (p calculated by Mann-Whitney test, 
CD14+CD16- versus CD14+CD16+ cells). On the right there is a representative image of the 
osteoclastogenesis assay stained by TRAP from BM sorted CD14+CD16- and CD14+CD16+ 
cells (Original magnification 4x). 
 
Figure 2: Transcriptional fingerprints evaluated by gene expression profiling of 
purified BM CD14+ cells from patients with different monoclonal gammopathies. 
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(A) Heatmap of the trancriptional profiles resulting from the unsupervised analysis of all the 
MM, SMM and MGUS monocyte samples. (B) Scatterplots visualize the correlation between 
IL21R expression and that of, CD40, SLAMF7 and CCR5 by BM monocytes arisen from gene 
expression analysis The lines represent the linear regression between each couple of genes. 
(C) Quantitative Real Time PCR of IL21R, CCR5, CD40 and SLAMF7 genes performed on 
BM monocytes samples purified from patients with monoclonal gammopathies. Values 
represent the median of the -∆Ct values of the reactions (*: fold change >1.5). (D) 
Quantitative Real Time PCR of IL21R, CCR5, CD40 and SLAMF7 genes performed on BM 
monocytes samples purified from MM patients with (w) or without (w/o) osteolysis. Values 
represent the mean of the -∆Ct values of the reactions. 
 
Figure 3: IL-21R over-expression by BM CD14+ cells in MM compared to SMM and 
MGUS patients. 
(A) IL21R mRNA expression was evaluated by Real Time PCR in purified BM CD14+ 
obtained from patients with monoclonal gammopathies. Box plot shows the median –ΔCt 
levels (p calculated by Mann-Whitney test). (B) IL21R mRNA expression was evaluated by 
Real Time PCR in purified BM CD14+ obtained from MM patients versus SMM+MGUS 
patients. Box plot shows the median –ΔCt levels (p calculated by Mann-Whitney test). (C) 
CD360/IL-21R expression was evaluated by flow cytometry in BM CD14+CD16- and 
CD14+CD16+ cells as shown for a representative MM patient. Flow cytometry analysis of 
CD360 expression by CD14+CD16- cells (i) and CD14+CD16+ cells (ii) stained with anti-
CD360 or control IgG1. (iii) Comparison between CD360 expression by CD14+CD16- and 
CD14+CD16+ monocyte populations (MFI: median fluorescence intensity). (D) Active 
STAT3 levels were determined by the STAT family assay kit in nuclear extracts of purified 
BM CD14+ cells obtained from MGUS (n=3), SMM (n=3) and MM (n=3) patients. Bar chart 
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represents the mean±SD level of active STAT3 checked as optical density (OD) at 450 nm 
with a reference wavelength of 620 nm, after subtracting the blank. (E) BM CD14+ cells 
purified from patients with MM, SMM or MGUS were treated with or without rhIL-21 
(30pg/ml) for 24 h. IL21R mRNA level was evaluated by Real Time PCR. Bar chart 
represents the median –ΔCt of IL21R mRNA of three replicates (Con: untreated control). (F) 
The monocytic cell line THP-1 was treated for 48 h with or without rhIL-6 (20ng/ml) or 
TNF-α (10ng/ml) or both cytokines. IL21R mRNA levels were evaluated by Real Time PCR 
in 3 independent experiments (p calculated by t test). Bar chart represents the mean±SD fold 
change of mRNA IL21R (Con: untreated control). 
 
Figure 4: IL21 mRNA expression by BM microenvironment and IL-21 BM levels in 
patients with MM, SMM and MGUS. 
(A) IL21 mRNA expression by purified CD3+ cells from MM (n=5), SMM (n=7) or MGUS 
(n=7) patients evaluated by Real Time PCR. Bar chart shows the mean±SD –ΔCt of IL21 
mRNA. (B) BM IL-21 levels were evaluated by ELISA assay in a cohort of 76 newly 
diagnosed MM, 42 SMM and 41 MGUS patients. Scatter dot plot represents BM IL-21 levels 
in the cohort of patients with the lines representing median levels. 
 
Figure 5: IL21R over-expression by a lentiviral vector in monocytes increases the OC 
differentiation. 
(A) IL21R over-expression was performed in PB CD14+ cells obtained from 3 different 
healthy donors transduced with a specific lentiviral vector for IL21R (CD14+ IL21R vector) 
as compared to those infected with the empty control vector (CD14+ empty vector) or not 
transduced (CD14+). IL21R mRNA levels were checked by Real Time PCR. Bar graph 
represents the median –ΔCt levels of 3 independent experiments. CD14+ transduced cells 
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with IL21R or empty lentiviral vectors (200.000 cells/well) were seeded in 96 well plates in 
αMEM medium at 10% FBS with rhM-CSF 10 ng/ml and rhRANKL 50 ng/ml in the 
presence or absence of the IL-21R signaling inhibitor Janex 1 (10 µM) or vehicle (DMSO). 
After 28 days of culture, OCs were identified as multinucleated (>3 nuclei) TRAP positive 
cells and counted by light microscopy. (B) Bar graph shows the mean±SD OC number for 
each well (p calculated by t test) in 3 independent experiments with CD14+ from 3 different 
healthy donors (left panel). Box plot represents the OC area (p calculated by Mann-Whitney 
test) in a representative experiment performed at least in triplicate (right panel). (C) Images 
of the osteoclastogenesis assay stained by TRAP of CD14+ IL21R vector and CD14+ cells 
empty vector performed in the presence or absence of Janex 1 of one representative 
experiment (Original magnification 4x). 
 
Figure 6: IL-21R signaling inhibition blocks IL-21R driven osteoclastogenesis. 
BM MNCs, obtained from MM patients, were seeded at the concentration of 4x105 cells/well 
in 96 well plates in αMEM medium at 10% FBS with rhM-CSF 25 ng/ml and rhRANKL 20 
ng/ml in presence or absence of rIL-21 (30 pg/ml) and the IL-21R signaling inhibitor Janex 1 
(10 µM) or vehicle (DMSO) for 28 days, replacing the medium every 3 days. At the end of 
culture period OCs were identified as multinucleated (>3 nuclei) TRAP positive cells and 
counted by light microscopy (Con: untreated control). (A) Bar graph represents the mean±SD 
OC number for each well (p calculated by t test) (upper panel). Box plot shows the OC area 
(p calculated by Mann-Whitney test) in one representative experiment performed at least in 
triplicate (lower panel). (B) Representative images of OCs stained with TRAP after 28 days 
of culture (Original magnification 4x). 
 
 
 






SUPPLEMENTAL METHODS 
Immunophenotype of BM CD14
+
 in patients with monoclonal gammopathies.  
Briefly, 100 μl of total BM aspirate was incubated in the dark with anti-human HLA-DR-PE (clone 
L243; BD), anti-human CD14-PerCP-Cy 5.5, anti-human CD16-PE-Cy7 (clone B73.1; BD) and 
anti-human CD45-APC-H 7 (clone 2D1; BD) for 20 min. Flow cytometry analysis was performed 
as 6-color experiment by using BD FACS Canto II with Diva software. First, a gate was set around 
monocytes based on their light-scatter properties. Then, two monocyte populations were defined in 
that gate: the classical CD14
bright
CD16
-
 monocytes and CD14
dim
CD16
bright
 monocytes. In some 
experiments, 10
6
 mononuclear cells (MNCs), obtained from BM aspirates by density gradient 
centrifugation (Lympholite-H; Burlington, NC), were stained with anti-human CD14-PerCP-Cy 5.5, 
anti-human CD16-PE-Cy7 and anti-human CD360/IL-21R APC (Clone 17A12; BD), using the 
gating strategy described above. 
Fluorescence in situ hybridization (FISH) analysis. 
FISH analysis has been performed on purified CD138
+
 cells to test the presence of: hyperdiploidy 
(ON9RED/15GREEN; Kreatech Diagnostics; Durham, NC); del(13q) (D13 S319SO/CEP 12SG; 
Metasystems; Altlussheim, Germany); del(17p) (LSI ATM SG/p53SO; Metasystems); chromosome 
14 translocation (14 BREAK-APART; Metasystems). If samples were positive for chromosome 14 
translocation, the presence of t(4;14) (FGFR3SO/IGHSG; Abbott Laboratories; Abbott Park, IL), 
t(11;14) (LSI IGH/CCND1XT; Abbott Laboratories) and t(14;16) (IGH/MAF; Abbott Laboratories) 
were checked. 
Microarrays analysis 
Total RNA was extracted from BM CD14
+
 cells using the RNeasy total RNA isolation kit (Qiagen; 
Hilden, Germany). Gene expression profiles of BM CD14
+
 cells previously isolated were generated 
on GeneChip
®
 HG-U133 Plus 2.0 arrays (Affymetrix; Santa Clara, CA). The biotin-labeled cRNA 
was prepared according to the Affymetrix GeneChip Expression Analysis Technical Manual 
protocol. Log2-transformed expression values were extracted from CEL files and normalized using 
RMA procedure in the affy package for Bioconductor and the annotations included in the cdf 
definition files version 20 available at the Brainarray portal 
(http://brainarray.mbni.med.umich.edu/Brainarray/Database/CustomCDF/20.0.0/version.html). 
Unsupervised and supervised analyses of gene expression data were carried out using the 
Signiﬁcant Analysis of Microarrays (SAM) software version 4.00, as previously reported.13  
Data were deposited in NCBI’s Gene Expression Omnibus and are accessible through GEO series 
accession number GSE70345. 
Correlation between IL21R expression and that of CCR5, CD40 and SLAMF7 by BM monocytes 
arisen from gene expression analysis were evaluated by Spearman rho correlation test. 
Real Time PCR. 
RNA (0,5 µg) was reverse-transcribed with 400 U Moloney murine leukemia reverse transcriptase 
(Applied Biosystems, Life Technologies) in accordance with the manufacturer’s protocol. Real 
Time PCR was performed by adding complementary DNA to a universal master Mix primers and 
TaqMan probes (Applied Biosystems) for the following genes: IL21R: Hs00222310_m1, SLAMF7: 
Hs00221793_m1 and ABL: Hs01104728_m1. The Real Time ready assays for CCR5 (Assay ID: 
104069) and CD40 (Assay ID: 100254) genes were purchased from Roche Diagnostics (Mannheim, 
Germany). The expression of selected genes was checked by Real Time PCR by Light Cycler 480 
(Roche Diagnostics). To normalize the differences in RNA quality and reverse transcription 
efficiency, we applied the comparative Ct method using the endogenous reference gene ABL. In the 
experiments where treated cells were compared to untreated controls, the fold change in mRNA 
expression (n-fold) of each analyzed gene was calculated as 2
-ΔΔCt
, as previously described.
30
 
However, when the aim of the analysis was to check the differences between groups of patients, 
mRNA expression levels were expressed as –ΔCt. 
STAT3 activity assay. 
STAT3 activity was evaluated by means of an ELISA-based commercially available kit (Trans AM 
STAT Family, Active Motif, Vinci Biochem; Vinci, Florence, Italy), used in accordance with the 
manufacturers’ procedures. We tested duplicates of nuclear extracts (each containing 5 µg of 
proteins) of CD14
+
 cells purified from 3 MGUS, 3 SMM and 3 MM patients and nuclear extracts of 
HepG2 treated with rhIL-6 (100 ng/ml) were used as positive controls, as suggested in the 
manufacturers’ procedures. Cell nuclear extracts were obtained and total amount of proteins 
quantified as previously described.
30 
BM IL-21 levels in patients with monoclonal gammopathies. 
The levels of IL-21 in BM plasma were measured in a total cohort of 76 newly diagnosed MM, 42 
SMM and 41 MGUS patients. Plasma (5 ml) was obtained after centrifugation from BM aspirates, 
aliquoted and stored at -20°C until analysis. BM IL-21 plasma levels were detected by Human 
Interleukin-21 ELISA kit (BioVendor; Brno, Czech Republic), following the manufacturers’ 
protocol. 
  
SUPPLEMENTAL TABLES 
Supplemental Table 1: mRNA expression levels of CD14 (929_at) and SDC1 (6382_at). 
Monocyte samples reported in italic style were excluded from gene expression analysis due to high 
PC contamination according to 2-groups stratification based on K-means clustering of SDC1 
expression.  
Monocyte sample CD14 SDC1 
MGUS1 8789.818 40.304 
MGUS2 9006.552 38.80391 
MGUS3 6403.874 35.66097 
MGUS4 9964.512 43.99736 
MGUS5 8146.314 59.22493 
MGUS6 8589.581 57.34123 
MGUS7 7803.366 44.29881 
MGUS8 9120.798 35.85622 
MGUS9 8895.179 32.07205 
SMM1 8114.306 37.218 
SMM2 8029.939 39.68942 
SMM3 7796.826 28.66408 
SMM4 9010.986 43.27907 
SMM5 8058.92 43.83396 
SMM6 9088.744 52.35158 
SMM7 7662.433 43.14486 
SMM8 5344.555 46.07221 
SMM9 8406.226 36.69782 
SMM10 11324.39 60.34423 
SMM11 9027.734 48.58276 
SMM12 7547.065 37.88982 
SMM13 7526.294 65.80806 
SMM14 8964.173 28.70343 
SMM15 8211.26 45.07396 
MM1 7492.444 32.61221 
MM2 6873.478 163.3324 
MM3 6079.989 42.57115 
MM4 8406.226 70.01866 
MM5 6458.982 49.30689 
MM6 5512.166 55.35385 
MM7 10195.97 37.92994 
MM8 8460.027 33.74889 
MM9 7921.082 80.19244 
MM10 7397.48 47.13206 
MM11 11284.27 30.44155 
MM12 7538.09 64.00715 
MM13 8060.529 100.2527 
MM14 9567.787 37.23853 
MM15 8702.203 166.6147 
MM16 8484.997 99.10607 
MM17 8436.607 35.66015 
MM18 8612.851 35.29721 
MM19 5049.836 56.44912 
MM20 8848.109 74.04942 
MM21 7571.708 61.97922 
MM22 9838.354 104.0483 
MM23 9886.636 45.53263 
MM24 4579.45 655.08 
MM25 5069.29 1464.04 
MM26 7199.53 1209.62 
MM27 1372.92 7674.54 
MM28 7325.70 702.92 
MM29 8592.04 1117.68 
MM30 7947.35 2153.92 
MM31 5844.00 555.92 
MM32 5309.73 2219.51 
Abbreviations: MGUS, Monoclonal Gammopathy of Undetermined Significance; SMM, 
Smoldering Multiple Myeloma; MM, Multiple Myeloma. 
  
Supplemental Table 2: List of genes significantly modulated in BM monocytes across the three 
groups of patients (MM, SMM and MGUS) by multiclass analysis of gene expression data. 
 
Gene ID Gene Name 
SAM 
Score(d)* 
FCER1A Fc fragment of IgE receptor Ia 1.49 
SLCO4C1 solute carrier organic anion transporter family member 4C1 1.46 
PTPN22 protein tyrosine phosphatase, non-receptor type 22 1.45 
PADI4 peptidyl arginine deiminase 4 1.45 
SLAMF7 SLAM family member 7 1.44 
PGM1 phosphoglucomutase 1 1.38 
RAB37 RAB37, member RAS oncogene family 1.34 
RPS17 ribosomal protein S17 1.33 
FLVCR2 
feline leukemia virus subgroup C cellular receptor family member 
2 
1.33 
ANXA6 annexin A6 1.32 
SERPINB10 serpin family B member 10 1.32 
WLS wntless Wnt ligand secretion mediator 1.31 
CLTCL1 clathrin heavy chain like 1 1.29 
TMEM55A transmembrane protein 55A 1.26 
SSBP4 single stranded DNA binding protein 4 1.25 
GNGT2 G protein subunit gamma transducin 2 1.22 
LOC100506844 uncharacterized LOC100506844 1.22 
CPNE2 copine 2 1.22 
CCR5 C-C motif chemokine receptor 5  1.21 
UBR4 ubiquitin protein ligase E3 component n-recognin 4 1.21 
SQLE squalene epoxidase 1.20 
CTSL cathepsin L 1.20 
SLC9A3R1 SLC9A3 regulator 1 1.20 
PNMA1 paraneoplastic Ma antigen 1 1.19 
LGALS12 galectin 12 1.19 
CHST7 carbohydrate sulfotransferase 7 1.19 
LHFPL2 lipoma HMGIC fusion partner-like 2 1.19 
MYB MYB proto-oncogene, transcription factor 1.19 
ADA adenosine deaminase 1.18 
SRPK1 SRSF protein kinase 1 1.17 
CENPK centromere protein K 1.17 
RUNX3 runt related transcription factor 3 1.17 
VAMP5 vesicle associated membrane protein 5 1.16 
IL21R interleukin 21 receptor 1.16 
HADHA 
hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-
CoA hydratase , alpha subunit 
1.15 
TMEM170B transmembrane protein 170B 1.14 
FBN2 fibrillin 2 1.14 
NCAPD2 non-SMC condensin I complex subunit D2 1.14 
MTSS1 MTSS1, I-BAR domain containing 1.13 
CCL18 C-C motif chemokine ligand 18 1.13 
EIF2D eukaryotic translation initiation factor 2D 1.13 
TCN2 transcobalamin 2 1.12 
DGKZ diacylglycerol kinase zeta 1.12 
AZU1 azurocidin 1 1.12 
SLC2A9 solute carrier family 2 member 9 1.11 
CDCA7 cell division cycle associated 7 1.11 
TUBB tubulin beta class I 1.11 
SPNS3 sphingolipid transporter 3  1.10 
TMEM51 transmembrane protein 51 1.10 
KBTBD11 kelch repeat and BTB domain containing 11 1.10 
IPCEF1 interaction protein for cytohesin exchange factors 1 1.10 
ECRP ribonuclease A family member 2 pseudogene 1.10 
SCCPDH saccharopine dehydrogenase  1.09 
ORM1 orosomucoid 1 1.08 
GAS2L1 growth arrest specific 2 like 1 1.08 
ANP32E acidic nuclear phosphoprotein 32 family member E 1.08 
ADAMTS5 ADAM metallopeptidase with thrombospondin type 1 motif 5 1.08 
GOT2 glutamic-oxaloacetic transaminase 2 1.08 
MIR205 microRNA 205 1.07 
NECTIN2 nectin cell adhesion molecule 2 1.07 
KIF11 kinesin family member 11 1.07 
NRM nurim  1.07 
CTSV cathepsin V 1.07 
SIPA1L2 signal induced proliferation associated 1 like 2 1.07 
SLC26A8 solute carrier family 26 member 8 1.07 
EMB embigin 1.06 
FAM101B refilin B 1.06 
MKI67 marker of proliferation Ki-67 1.06 
CDCA7L cell division cycle associated 7 like 1.06 
HEG1 heart development protein with EGF like domains 1 1.06 
B4GALT6 beta-1,4-galactosyltransferase 6 1.05 
IGF1R insulin like growth factor 1 receptor 1.05 
DNASE2 deoxyribonuclease 2, lysosomal 1.05 
IFNGR2 interferon gamma receptor 2  1.05 
SELM selenoprotein M 1.05 
EIF3L eukaryotic translation initiation factor 3 subunit L 1.05 
TRAF5 TNF receptor associated factor 5 1.05 
TMC8 transmembrane channel like 8 1.05 
E2F8 E2F transcription factor 8 1.05 
PRRG2 proline rich and Gla domain 2 1.05 
CIT citron rho-interacting serine/threonine kinase 1.04 
PTCH1 patched 1 1.04 
PSRC1 proline and serine rich coiled-coil 1 1.04 
INSIG1 insulin induced gene 1 1.04 
MRPL37 mitochondrial ribosomal protein L37 1.04 
RRAS related RAS viral  oncogene homolog 1.04 
MAP4K4 mitogen-activated protein kinase kinase kinase kinase 4 1.04 
PIM1 Pim-1 proto-oncogene, serine/threonine kinase 1.03 
IFITM1 interferon induced transmembrane protein 1 1.03 
HIP1 huntingtin interacting protein 1 1.03 
ANLN anillin actin binding protein 1.03 
PGD phosphogluconate dehydrogenase 1.03 
SPOCK1 SPARC/osteonectin, cwcv and kazal like domains proteoglycan 1 1.03 
ISG20 interferon stimulated exonuclease gene 20 1.03  
LOC152225 uncharacterized LOC152225 1.03 
BPI bactericidal/permeability-increasing protein 1.03 
CKAP4 cytoskeleton associated protein 4 1.03 
ZBED3 zinc finger BED-type containing 3 1.02 
PKM pyruvate kinase, muscle 1.02 
*Linear discriminant score defined by the Significance Analysis of Microarrays (SAM) analysis. 
  
Supplemental Table 3: List of genes differentially expressed by BM monocytes obtained from 
supervised analysis of MM patients as compared to SMM. 
 
DOWN 
 
  
Gene ID Gene Name 
SAM 
score(d)* 
Fold 
Change 
PTPN22 protein tyrosine phosphatase, non-receptor type 22 -4.76 0.59 
PADI4 peptidyl arginine deiminase 4 -4.65 0.44 
FCER1A Fc fragment of IgE receptor Ia -4.62 0.42 
SLCO4C1 
solute carrier organic anion transporter family member 
4C1 
-4.57 0.45 
RAB37 RAB37, member RAS oncogene family -4.54 0.58 
ECRP ribonuclease A family member 2 pseudogene -4.46 0.47 
SERPINB10 serpin family B member 10 -4.38 0.29 
PGM1 phosphoglucomutase 1 -4.29 0.64 
RPS17 ribosomal protein S17 -4.29 0.79 
FBN2 fibrillin 2 -4.18 0.54 
LGALS12 galectin 12 -4.16 0.60 
ANXA6 annexin A6 -4.08 0.65 
MIR205 microRNA 205 -4.02 0.76 
SPNS3 sphingolipid transporter 3 -3.99 0.64 
TMEM55A transmembrane protein 55A -3.98 0.67 
SCCPDH saccharopine dehydrogenase -3.97 0.72 
ADAMTS5 
ADAM metallopeptidase with thrombospondin type 1 
motif 5 
-3.97 0.73 
SLC2A9 solute carrier family 2 member 9 -3.96 0.74 
WLS wntless Wnt ligand secretion mediator -3.92 0.64 
KBTBD11 kelch repeat and BTB domain containing 11 -3.88 0.66 
SRPK1 SRSF protein kinase 1 -3.86 0.69 
PGD phosphogluconate dehydrogenase -3.85 0.72 
SLC26A8 solute carrier family 26 member 8 -3.85 0.66 
UBR4 ubiquitin protein ligase E3 component n-recognin 4 -3.82 0.74 
LOC100506844 uncharacterized LOC100506844 -3.78 0.62 
SLC9A3R1 SLC9A3 regulator 1 -3.78 0.70 
CLTCL1 clathrin heavy chain like 1 -3.76 0.70 
CENPK centromere protein K -3.73 0.43 
MYB MYB proto-oncogene, transcription factor -3.71 0.51 
EMB embigin -3.70 0.55 
TMC8 transmembrane channel like 8 -3.68 0.74 
EIF2D eukaryotic translation initiation factor 2D -3.61 0.78 
MTMR11 myotubularin related protein 11 -3.60 0.63 
BPI bactericidal/permeability-increasing protein -3.55 0.42 
MRPL33 mitochondrial ribosomal protein L33 -3.53 0.81 
NRM nurim -3.52 0.79 
FMO5 flavin containing monooxygenase 5 -3.52 0.72 
HIP1 huntingtin interacting protein 1 -3.52 0.75 
KIF21B kinesin family member 21B -3.51 0.78 
B4GALT6 beta-1,4-galactosyltransferase 6 -3.49 0.77 
DGKZ diacylglycerol kinase zeta -3.49 0.74 
CDA cytidine deaminase -3.48 0.65 
HDDC2 HD domain containing 2 -3.46 0.78 
MARC1 mitochondrial amidoxime reducing component 1 -3.46 0.61 
MAP4K4 mitogen-activated protein kinase kinase kinase kinase 4 -3.46 0.79 
TMEM170B transmembrane protein 170B -3.43 0.62 
CPNE2 copine 2 -3.43 0.73 
ADGRA2 adhesion G protein-coupled receptor A2 -3.43 0.70 
IPCEF1 interaction protein for cytohesin exchange factors 1 -3.42 0.61 
CACNA2D3 
calcium voltage-gated channel auxiliary subunit 
alpha2delta 3 
-3.41 0.60 
MAP4K1 mitogen-activated protein kinase kinase kinase kinase 1 -3.41 0.74 
CDCA7 cell division cycle associated 7 -3.41 0.50 
PKM pyruvate kinase, muscle -3.40 0.69 
RNASE2 ribonuclease A family member 2 -3.40 0.58 
PSRC1 proline and serine rich coiled-coil 1 -3.40 0.73 
CKAP4 cytoskeleton associated protein 4 -3.39 0.65 
FAM101B refilin B -3.39 0.62 
SPOCK1 
SPARC/osteonectin, cwcv and kazal like domains 
proteoglycan 1 
-3.38 0.65 
NME8 NME/NM23 family member 8 -3.38 0.74 
CYTL1 cytokine like 1 -3.37 0.62 
    
UP    
Gene ID Gene Name 
SAM 
score(d)* 
Fold 
Change 
SLAMF7 SLAM family member 7 4.74 2.44 
CCR5 C-C motif chemokine receptor 5 4.55 2.26 
CTSL cathepsin L 4.46 2.13 
CHST7 carbohydrate sulfotransferase 7 4.33 1.87 
LHFPL2 lipoma HMGIC fusion partner-like 2 4.15 2.20 
PNMA1 paraneoplastic Ma antigen 1 4.07 1.55 
SSBP4 single stranded DNA binding protein 4 4.06 1.28 
PIM1 Pim-1 proto-oncogene, serine/threonine kinase 4.03 1.63 
GAS2L1 growth arrest specific 2 like 1 3.98 1.37 
GNGT2 G protein subunit gamma transducin 2 3.97 1.40 
TCN2 transcobalamin 2 3.91 1.50 
FLVCR2 
feline leukemia virus subgroup C cellular receptor family 
member 2 
3.90 1.51 
YES1 YES proto-oncogene 1, Src family tyrosine kinase 3.87 1.22 
SQLE squalene epoxidase 3.86 1.84 
VAMP5 vesicle associated membrane protein 5 3.85 1.62 
ADA adenosine deaminase 3.83 1.79 
CTSV cathepsin V 3.81 1.43 
IFNGR2 interferon gamma receptor 2 3.75 1.38 
*Ratio of change in gene expression to standard deviation.  
Supplemental Table 4: List of differentially expressed genes by BM monocytes arisen from 
supervised analysis of MM versus (MGUS plus SMM) patients. 
 
DOWN 
 
  
Gene ID Gene Name 
SAM 
Score(d)* 
Fold 
Change 
FCER1A Fc fragment of IgE receptor Ia  -5.70 0.40 
SLCO4C1 
solute carrier organic anion transporter family member 
4C1 
-5.65 0.45 
PADI4 peptidyl arginine deiminase 4  -5.58 0.46 
PTPN22 protein tyrosine phosphatase, non-receptor type 22  -5.57 0.60 
PGM1 phosphoglucomutase 1  -5.35 0.64 
RPS17 ribosomal protein S17 -5.15 0.79 
ANXA6 annexin A6  -5.12 0.64 
RAB37 RAB37, member RAS oncogene family -5.12 0.60 
WLS wntless Wnt ligand secretion mediator  -5.03 0.63 
SERPINB10 serpin family B member 10  -5.01 0.32 
CLTCL1 clathrin heavy chain like 1 -4.92 0.68 
TMEM55A transmembrane protein 55A -4.89 0.67 
LOC100506844 uncharacterized LOC100506844  -4.71 0.62 
UBR4 ubiquitin protein ligase E3 component n-recognin 4  -4.66 0.74 
SLC9A3R1 SLC9A3 regulator 1  -4.63 0.70 
CPNE2 copine 2 -4.59 0.71 
MYB MYB proto-oncogene, transcription factor -4.58 0.51 
CENPK centromere protein K -4.54 0.43 
SRPK1 SRSF protein kinase 1 -4.53 0.70 
LGALS12 galectin 12 -4.52 0.63 
TMEM170B transmembrane protein 170B -4.40 0.61 
HADHA 
hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA 
thiolase/enoyl-CoA hydratase , alpha subunit  
-4.38 0.83 
EIF2D eukaryotic translation initiation factor 2D -4.37 0.78 
DGKZ diacylglycerol kinase zeta  -4.33 0.74 
CDCA7 cell division cycle associated 7  -4.29 0.50 
FBN2 fibrillin 2 -4.26 0.58 
AZU1 azurocidin 1 -4.25 0.45 
IPCEF1 interaction protein for cytohesin exchange factors 1  -4.25 0.61 
TUBB tubulin beta class I -4.23 0.68 
SPNS3 sphingolipid transporter 3  -4.23 0.65 
NCAPD2 non-SMC condensin I complex subunit D2  -4.22 0.59 
ANP32E acidic nuclear phosphoprotein 32 family member E  -4.17 0.72 
ADAMTS5 
ADAM metallopeptidase with thrombospondin type 1 
motif 5 
-4.17 0.72 
ORM1 orosomucoid 1 -4.17 0.49 
KIF11 kinesin family member 11  -4.14 0.40 
NRM nurim  -4.14 0.79 
KBTBD11 kelch repeat and BTB domain containing 11  -4.13 0.69 
GOT2 glutamic-oxaloacetic transaminase 2 -4.13 0.75 
SLC2A9 solute carrier family 2 member 9  -4.12 0.76 
FAM101B refilin B -4.11 0.63 
EMB embigin  -4.10 0.56 
CDCA7L cell division cycle associated 7 like  -4.08 0.54 
SLC26A8 solute carrier family 26 member 8  -4.07 0.68 
B4GALT6 beta-1,4-galactosyltransferase 6  -4.07 0.77 
E2F8 E2F transcription factor 8 -4.05 0.44 
MKI67 marker of proliferation Ki-67 -4.04 0.54 
EIF3L eukaryotic translation initiation factor 3 subunit L -4.04 0.81 
PSRC1 proline and serine rich coiled-coil 1 -4.00 0.74 
MRPL37 mitochondrial ribosomal protein L37  -3.99 0.84 
ANLN anillin actin binding protein -3.99 0.44 
SPOCK1 
SPARC/osteonectin, cwcv and kazal like domains 
proteoglycan 1  
-3.97 0.66 
MAP4K4 mitogen-activated protein kinase kinase kinase kinase 4  -3.96 0.80 
ZBED3 zinc finger BED-type containing 3  -3.95 0.70 
HIP1 huntingtin interacting protein 1 -3.94 0.76 
CKAP4 cytoskeleton associated protein 4  -3.93 0.67 
CIT citron rho-interacting serine/threonine kinase  -3.92 0.65 
PKM pyruvate kinase, muscle -3.92 0.71 
RAB27A RAB27A, member RAS oncogene family -3.90 0.71 
ZWINT ZW10 interacting kinetochore protein  -3.90 0.49 
FOXM1 forkhead box M1  -3.89 0.61 
S100A12 S100 calcium binding protein A12  -3.89 0.69 
CENPH centromere protein H -3.87 0.59 
MS4A3 membrane spanning 4-domains A3  -3.87 0.43 
PECR peroxisomal trans-2-enoyl-CoA reductase -3.86 0.67 
TOP2A topoisomerase  II alpha -3.86 0.40 
CDA cytidine deaminase -3.84 0.67 
CENPF centromere protein F -3.83 0.55 
LOC100288637 OTU deubiquitinase 7A pseudogene  -3.82 0.59 
BPI bactericidal/permeability-increasing protein  -3.82 0.46 
SCCPDH saccharopine dehydrogenase  -3.82 0.76 
GPSM2 G-protein signaling modulator 2  -3.82 0.63 
TMC8 transmembrane channel like 8  -3.81 0.77 
ZNF281 zinc finger protein 281 -3.81 0.73 
MRPL33 mitochondrial ribosomal protein L33  -3.80 0.81 
MIR205 microRNA 205  -3.80 0.79 
MARC1 mitochondrial amidoxime reducing component 1 -3.79 0.65 
HIPK2 homeodomain interacting protein kinase 2  -3.79 0.75 
KIF18B kinesin family member 18B  -3.78 0.50 
NCAPG non-SMC condensin I complex subunit G  -3.78 0.47 
RETN resistin -3.78 0.58 
TPCN1 two pore segment channel 1 -3.77 0.81 
TYMS thymidylate synthetase  -3.77 0.44 
RACGAP1 Rac GTPase activating protein 1  -3.77 0.56 
SHCBP1 SHC binding and spindle associated 1 -3.77 0.56 
GINS1 GINS complex subunit 1 -3.76 0.51 
CACNA2D3 
calcium voltage-gated channel auxiliary subunit 
alpha2delta 3 
-3.76 0.63 
PTDSS1 phosphatidylserine synthase 1  -3.76 0.82 
ECRP ribonuclease A family member 2 pseudogene -3.75 0.54 
PGD phosphogluconate dehydrogenase -3.75 0.76 
KIAA0101 KIAA0101 -3.74 0.46 
MSL1 male specific lethal 1 homolog -3.74 0.81 
TPX2 TPX2, microtubule nucleation factor -3.73 0.48 
TK1 thymidine kinase 1 -3.73 0.66 
FAM217B family with sequence similarity 217 member B -3.73 0.67 
NUSAP1 nucleolar and spindle associated protein 1 -3.73 0.51 
NCAPG2 non-SMC condensin II complex subunit G2 -3.72 0.62 
KIF20A kinesin family member 20A -3.72 0.47 
BMX BMX non-receptor tyrosine kinase -3.71 0.72 
KIF15 kinesin family member 15 -3.70 0.50 
HMGB2 high mobility group box 2 -3.69 0.78 
IGF1R insulin like growth factor 1 receptor -3.69 0.73 
NME8 NME/NM23 family member 8 -3.68 0.76 
KIFC1 kinesin family member C1 -3.68 0.72 
MEGF9 multiple EGF like domains 9 -3.68 0.62 
OIP5 Opa interacting protein 5 -3.68 0.54 
MAP4K1 mitogen-activated protein kinase kinase kinase kinase 1 -3.67 0.76 
ADGRA2 adhesion G protein-coupled receptor A2 -3.67 0.71 
CEP55 centrosomal protein 55 -3.67 0.47 
TACC3 transforming acidic coiled-coil containing protein 3 -3.65 0.75 
NUF2 NUF2, NDC80 kinetochore complex component -3.64 0.50 
RASSF1 Ras association domain family member 1 -3.64 0.82 
GPI glucose-6-phosphate isomerase -3.64 0.79 
CENPM centromere protein M -3.63 0.62 
ZNF367 zinc finger protein 367 -3.62 0.51 
EFCAB2 EF-hand calcium binding domain 2 -3.61 0.67 
CTH cystathionine gamma-lyase -3.61 0.53 
KIF21B kinesin family member 21B -3.60 0.80 
HIST1H4C histone cluster 1 H4 family member c -3.60 0.57 
PCNA proliferating cell nuclear antigen -3.59 0.62 
MTMR11 myotubularin related protein 11 -3.59 0.68 
TMC4 transmembrane channel like 4 -3.58 0.72 
C20orf27 chromosome 20 open reading frame 27 -3.58 0.78 
PLD1 phospholipase D1 -3.58 0.81 
UBE2C ubiquitin conjugating enzyme E2 C -3.57 0.54 
TTK TTK protein kinase -3.57 0.50 
FAM110B family with sequence similarity 110 member B -3.56 0.76 
CBX4 chromobox 4 -3.56 0.78 
FARSB phenylalanyl-tRNA synthetase beta subunit -3.55 0.80 
MAD2L1 MAD2 mitotic arrest deficient-like 1  -3.54 0.54 
FMO5 flavin containing monooxygenase 5 -3.54 0.76 
ERG ERG, ETS transcription factor -3.53 0.85 
ANAPC15 anaphase promoting complex subunit 15 -3.53 0.82 
FAM64A family with sequence similarity 64 member A -3.52 0.70 
KIF14 kinesin family member 14 -3.51 0.55 
SLC25A40 solute carrier family 25 member 40 -3.51 0.75 
THBS4 thrombospondin 4 -3.50 0.79 
SSR1 signal sequence receptor subunit 1 -3.50 0.85 
POLR3B RNA polymerase III subunit B -3.50 0.79 
PCMT1 protein-L-isoaspartate  O-methyltransferase -3.49 0.78 
SIDT1 SID1 transmembrane family member 1 -3.48 0.71 
ITGAM integrin subunit alpha M -3.47 0.76 
CAT catalase -3.47 0.72 
NCL nucleolin -3.46 0.87 
LPGAT1 lysophosphatidylglycerol acyltransferase 1 -3.46 0.76 
CCNE2 cyclin E2 -3.45 0.62 
HAL histidine ammonia-lyase -3.45 0.73 
MCM7 minichromosome maintenance complex component 7 -3.45 0.72 
STMN1 stathmin 1 -3.44 0.79 
BIRC5 baculoviral IAP repeat containing 5 -3.44 0.64 
SDHD succinate dehydrogenase complex subunit D -3.44 0.82 
CDC20 cell division cycle 20 -3.43 0.50 
PHKA2 phosphorylase kinase regulatory subunit alpha 2 -3.43 0.83 
MPO myeloperoxidase -3.43 0.49 
BUB1B BUB1 mitotic checkpoint serine/threonine kinase B -3.43 0.55 
DTL denticleless E3 ubiquitin protein ligase homolog -3.43 0.51 
RRM2 ribonucleotide reductase regulatory subunit M2 -3.43 0.46 
TFF3 trefoil factor 3 -3.43 0.80 
VRK1 vaccinia related kinase 1 -3.42 0.74 
PTTG1 pituitary tumor-transforming 1 -3.42 0.64 
TSPAN2 tetraspanin 2 -3.42 0.69 
SLC40A1 solute carrier family 40 member 1 -3.42 0.45 
GYS1 glycogen synthase 1 -3.42 0.79 
KIF4A kinesin family member 4A -3.42 0.56 
NPIPB15 
nuclear pore complex interacting protein family member 
B15 
-3.41 0.73 
PLCL2 phospholipase C like 2 -3.41 0.77 
TOP1MT topoisomerase  I, mitochondrial -3.40 0.75 
TCF19 transcription factor 19 -3.40 0.67 
SFXN5 sideroflexin 5 -3.40 0.87 
MELK maternal embryonic leucine zipper kinase -3.39 0.56 
CYTL1 cytokine like 1 -3.39 0.65 
CSF3R colony stimulating factor 3 receptor -3.38 0.82 
MCM4 minichromosome maintenance complex component 4 -3.36 0.73 
USP48 ubiquitin specific peptidase 48 -3.36 0.78 
CDK1 cyclin dependent kinase 1 -3.35 0.54 
CIDEB cell death-inducing DFFA-like effector b -3.35 0.76 
CARS2 cysteinyl-tRNA synthetase 2, mitochondrial  -3.35 0.80 
IVNS1ABP influenza virus NS1A binding protein -3.34 0.74 
DLGAP5 DLG associated protein 5 -3.34 0.43 
TMEM106C transmembrane protein 106C -3.34 0.71 
RCC1 regulator of chromosome condensation 1 -3.33 0.85 
ASPM abnormal spindle microtubule assembly -3.33 0.54 
GTSE1 G2 and S-phase expressed 1 -3.32 0.73 
BZW2 basic leucine zipper and W2 domains 2 -3.32 0.83 
RNASE2 ribonuclease A family member 2 -3.32 0.63 
EP300-AS1 EP300 antisense RNA 1 -3.32 0.85 
SMC2 structural maintenance of chromosomes 2 -3.31 0.65 
RALGAPA2 Ral GTPase activating protein catalytic alpha subunit 2 -3.31 0.84 
CCNA2 cyclin A2 -3.31 0.55 
VILL villin like -3.30 0.83 
SSRP1 structure specific recognition protein 1 -3.30 0.82 
GGH gamma-glutamyl hydrolase -3.30 0.65 
SMYD2 SET and MYND domain containing 2 -3.30 0.81 
  
  
UP 
 
  
Gene ID Gene Name 
SAM 
Score(d)* 
Fold 
Change 
SLAMF7 SLAM family member 7  5.56 2.35 
FLVCR2 
feline leukemia virus subgroup C cellular receptor family 
member 2 
5.01 1.58 
SSBP4 single stranded DNA binding protein 4  4.81 1.29 
GNGT2 G protein subunit gamma transducin 2  4.71 1.41 
SQLE squalene epoxidase 4.64 1.81 
PNMA1 paraneoplastic Ma antigen 1  4.58 1.52 
ADA adenosine deaminase 4.55 1.75 
VAMP5 vesicle associated membrane protein 5 4.49 1.61 
IL21R interleukin 21 receptor 4.48 1.49 
RUNX3 runt related transcription factor 3 4.47 1.62 
LHFPL2 lipoma HMGIC fusion partner-like 2 4.44 2.03 
MTSS1 MTSS1, I-BAR domain containing 4.38 1.43 
TCN2 transcobalamin 2 4.25 1.45 
CTSL cathepsin L 4.22 1.87 
TMEM51 transmembrane protein 51 4.22 1.71 
CHST7 carbohydrate sulfotransferase 7 4.20 1.68 
CCR5 C-C motif chemokine receptor 5  4.20 1.95 
NECTIN2 nectin cell adhesion molecule 2 4.13 1.25 
HEG1 heart development protein with EGF like domains 1 4.08 1.51 
SIPA1L2 signal induced proliferation associated 1 like 2  4.07 1.34 
TRAF5 TNF receptor associated factor 5 4.05 1.36 
DNASE2 deoxyribonuclease 2, lysosomal  4.05 1.60 
INSIG1 insulin induced gene 1  4.01 1.69 
RRAS related RAS viral  oncogene homolog 4.01 1.48 
IFITM1 interferon induced transmembrane protein 1  4.00 2.52 
PTCH1 patched 1 3.99 1.12 
ISG20 interferon stimulated exonuclease gene 20  3.98 1.68 
LOC152225 uncharacterized LOC152225  3.97 1.43 
PIM1 Pim-1 proto-oncogene, serine/threonine kinase  3.96 1.58 
IFNGR2 interferon gamma receptor 2  3.95 1.34 
CD9 CD9 molecule 3.94 2.26 
PRRG2 proline rich and Gla domain 2 3.94 1.20 
LFNG 
LFNG O-fucosylpeptide 3-beta-N-
acetylglucosaminyltransferase  
3.92 1.37 
GAS2L1 growth arrest specific 2 like 1 3.91 1.31 
DHRS9 dehydrogenase/reductase 9 3.91 1.77 
PAPSS2 3'-phosphoadenosine 5'-phosphosulfate synthase 2 3.91 1.49 
CTSV cathepsin V 3.88 1.36 
MAP3K7CL MAP3K7 C-terminal like 3.87 1.94 
EPSTI1 epithelial stromal interaction 1  3.87 2.05 
STAT4 signal transducer and activator of transcription 4 3.83 1.40 
AMPD1 adenosine monophosphate deaminase 1 3.82 1.72 
CASP5 caspase 5 3.79 1.64 
MARCO macrophage receptor with collagenous structure  3.79 1.47 
CD40 CD40 molecule 3.78 1.29 
SELM selenoprotein M 3.78 1.55 
CACNA1A calcium voltage-gated channel subunit alpha1 A  3.77 1.25 
ZDHHC23 zinc finger DHHC-type containing 23  3.76 1.24 
HIVEP2 
human immunodeficiency virus type I enhancer binding 
protein 2 
3.75 1.34 
LINC00847 long intergenic non-protein coding RNA 847  3.74 1.42 
IDI1 isopentenyl-diphosphate delta isomerase 1 3.72 1.27 
PRORSD1P 
prolyl-tRNA synthetase associated domain containing 1, 
pseudogene  
3.72 1.22 
GJA3 gap junction protein alpha 3 3.71 1.16 
ADGRE2 adhesion G protein-coupled receptor E2 3.71 1.50 
TESK1 testis-specific kinase 1 3.70 1.21 
LAP3 leucine aminopeptidase 3 3.69 1.44 
MLLT11 
myeloid/lymphoid or mixed-lineage leukemia; 
translocated to, 11 
3.68 1.31 
SLC16A6 solute carrier family 16 member 6  3.67 1.50 
EIF5A2 eukaryotic translation initiation factor 5A2  3.66 1.29 
PIK3IP1 phosphoinositide-3-kinase interacting protein 1 3.64 1.21 
IFI27 interferon alpha inducible protein 27  3.62 3.13 
ERGIC1 endoplasmic reticulum-golgi intermediate compartment 1  3.60 1.25 
CXCL11 C-X-C motif chemokine ligand 11  3.60 2.01 
*Ratio of change in gene expression to standard deviation. 
 
Supplemental Table 5: IL-21 expression by BM microenvironment cells. 
 
-ΔCt 
BM MSCs ND 
CD14
+
 cells ND 
CD138
+
 cells ND 
CD3
+
 cells -8,3 
Activated CD3
+
 cells -1 
CD8
+
 cells ND 
CD4
+
 cells -8,6 
Abbreviation: ND=not detectable 
 
 
LEGENDS OF SUPPLEMENTAL FIGURES 
Supplemental Figure 1: BM monocytes purity. Representative flow cytometry plots to assess the 
purity of BM monocytes after purification with anti-CD14 Ab conjugated microbeads. Monocytes 
were identified as CD14
+
CD45
+
CD138
-
 cells. 
 
Supplemental Figure 2: Monocyte sub-population sorting. Example of flow cytometry analysis 
with anti-human CD16 and anti-human CD14, showing the two sub-population of monocytes 
before (A) and after (B, C) sorting. Purity of CD14
+
CD16
+
 (B) and CD14
+
CD16
-
 (C) cells. 
 
Supplemental Figure 3: Gene expression profiling of purified BM CD14
+
 cells from patients 
with different monoclonal gammopathies. (A) Heatmap of the differentially expressed genes 
resulted from the multiclass Signiﬁcant Analysis of Microarrays (SAM) of the monocytes samples 
clustered according to the diagnosis of the patients. Heatmaps of the differentially expressed genes 
arisen from the supervised SAM analyses comparing BM CD14
+ 
cells from MM versus SMM (B) 
or active MM versus asymptomatic forms (MGUS plus SMM) (C). 
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